Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W R Kim

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Annals of Internal Medicine|February 12, 1998
Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis CW R Kim, J J Poterucha, J E Hermans, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|July 29, 2000
Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidatesW R Kim, R H Wiesner, J J Poterucha, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|July 19, 2001
MELD and PELD: application of survival models to liver allocationR H Wiesner, S V McDiarmid, P S Kamath, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 4, 2020
OPTN/SRTR 2018 Annual Data Report: Hepatitis CJ H Wang, S K Gustafson, M A Skeans, et al.
Alimentary Pharmacology & Therapeutics|July 28, 2010
Daclizumab induction therapy in liver transplant recipients with renal insufficiencyS K Asrani, W R Kim, R A Pedersen, et al.
Hepatology (Baltimore, Md.)|February 15, 2001
A model to predict survival in patients with end-stage liver diseaseP S Kamath, R H Wiesner, M Malinchoc, et al.
Alimentary Pharmacology & Therapeutics|January 28, 2014
The impact of hepatitis C burden: an evidence-based approachZ M Younossi, F Kanwal, S Saab, et al.
Hepatology (Baltimore, Md.)|May 29, 1999
The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitisW R Kim, J J Poterucha, R H Wiesner, et al.
Mayo Clinic Proceedings|July 25, 2000
A revised natural history model for primary sclerosing cholangitisW R Kim, T M Therneau, R H Wiesner, et al.
Hepatology (Baltimore, Md.)|September 17, 2019
MELD-GRAIL-Na: Glomerular Filtration Rate and Mortality on Liver-Transplant Waiting ListSumeet K Asrani, Linda W Jennings, W R Kim, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Annals of Internal Medicine|February 12, 1998
Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis CW R Kim, J J Poterucha, J E Hermans, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|July 29, 2000
Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidatesW R Kim, R H Wiesner, J J Poterucha, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|July 19, 2001
MELD and PELD: application of survival models to liver allocationR H Wiesner, S V McDiarmid, P S Kamath, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 4, 2020
OPTN/SRTR 2018 Annual Data Report: Hepatitis CJ H Wang, S K Gustafson, M A Skeans, et al.
Alimentary Pharmacology & Therapeutics|July 28, 2010
Daclizumab induction therapy in liver transplant recipients with renal insufficiencyS K Asrani, W R Kim, R A Pedersen, et al.
Hepatology (Baltimore, Md.)|February 15, 2001
A model to predict survival in patients with end-stage liver diseaseP S Kamath, R H Wiesner, M Malinchoc, et al.
Alimentary Pharmacology & Therapeutics|January 28, 2014
The impact of hepatitis C burden: an evidence-based approachZ M Younossi, F Kanwal, S Saab, et al.
Hepatology (Baltimore, Md.)|May 29, 1999
The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitisW R Kim, J J Poterucha, R H Wiesner, et al.
Mayo Clinic Proceedings|July 25, 2000
A revised natural history model for primary sclerosing cholangitisW R Kim, T M Therneau, R H Wiesner, et al.
Hepatology (Baltimore, Md.)|September 17, 2019
MELD-GRAIL-Na: Glomerular Filtration Rate and Mortality on Liver-Transplant Waiting ListSumeet K Asrani, Linda W Jennings, W R Kim, et al.
Pageof 6